Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Squamous Cell Carcinoma of Head and Neck 4Mouth Neoplasms 3Laryngeal Neoplasms 3Hypopharyngeal Neoplasms 3Carcinoma 3Oropharyngeal Neoplasms 2Rectal Neoplasms 1Nasopharyngeal Carcinoma 1Lymphoid Interstitial Pneumonia 1Locally Recurrent Skin Squamous Cell Carcinoma 1Colorectal Neoplasms 1Colonic Neoplasms 1

Interventions

Oxaliplatin 11Leucovorin 10Fluorouracil 10Cetuximab 7Bevacizumab 7Specimen Handling 6Magnetic Resonance Spectroscopy 4pembrolizumab 3fludarabine 3Pemetrexed 3Nivolumab 3Irinotecan 3Cyclophosphamide 3encorafenib 2dehydroftorafur 2cemiplimab 2aldesleukin 2Surveys and Questionnaires 2Laparoscopy 2Immunoglobulin G 2Gemcitabine 2Folfox protocol 2Disulfides 2Conversion to Open Surgery 2Cisplatin 2Celecoxib 2Carboplatin 2Biopsy 2ulixertinib 1trifluridine tipiracil drug combination 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Colonic Neoplasms × (225)Ac-DOTA-c(RGDyK) × 30 days × Clear all
NCT05308446 2026-06-03

Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation

National Cancer Institute (NCI)

Phase 2 Active not recruiting
86 enrolled
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡